

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5980872

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YINGZHI BI	05/22/2018
BRUCE D. DORSEY	05/22/2018
CHRISTOPHER BROOKS MOORE	05/23/2018
RECEIVING PARTY DATA	
Name:	ARBUTUS BIOPHARMA, INC.
Street Address:	701 VETERANS CIRCLE
City:	WARMINSTER
State/Country:	PENNSYLVANIA
Postal Code:	18974
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16608133
CORRESPONDENCE DATA	
Fax Number:	(215)972-7725
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	215-972-1089
Email:	patents@saul.com
Correspondent Name:	DOMINGOS J. SILVA
Address Line 1:	SAUL EWING ARNSTEIN & LEHR LLP
Address Line 2:	1500 MARKET STREET, 38TH FLOOR
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19102
ATTORNEY DOCKET NUMBER:	367569-7008US1 (00100)
NAME OF SUBMITTER:	DOMINGOS J. SILVA
SIGNATURE:	/Domingos J. Silva/
DATE SIGNED:	02/25/2020
Total Attachments: 5	
source=367569-7008WO1_Executed_Assignment_Inventors_Arbutus_Inc#page1.tif	
source=367569-7008WO1_Executed_Assignment_Inventors_Arbutus_Inc#page2.tif	
source=367569-7008WO1_Executed_Assignment_Inventors_Arbutus_Inc#page3.tif	

source=367569-7008WO1_Executed_Assignment_Inventors_Arbutus_Inc#page4.tif

source=367569-7008WO1_Executed_Assignment_Inventors_Arbutus_Inc#page5.tif

ASSIGNMENT

WHEREAS, WE, **Yingzhi BI**, a citizen of the United States of America, having a mailing address of 5 Mershon Lane, Plainsboro, NJ 08536; **Bruce D. DORSEY**, a citizen of the United States of America, having a mailing address of 1213 Meetinghouse Road, Ambler, PA 19002; and **Christopher Brooks MOORE**, a citizen of the United States of America, having a mailing address of 1508 Snowdrop Circle, Jamison, PA 18929; and hereinafter generally referred to as "ASSIGNORS," have invented a certain new and useful:

**SUBSTITUTED 2,3-DIHYDRO-1H-INDENE ANALOGS
AND METHODS USING SAME**

for which We have executed PCT International Patent Application No. PCT/US2018/029202, filed April 24, 2018, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62/489,870, on April 25, 2017.

WHEREAS, **Arbutus Biopharma, Inc.**, having a place of business at 701 Veterans Circle, Warminster, PA 18974, United States of America, hereinafter generally referred to as "ASSIGNEE," is desirous of acquiring said invention and said patent application.

NOW, THEREFORE, in consideration of the sum of One Dollar and other good and valuable executed consideration, the full receipt and sufficiency of all of which are hereby acknowledged and intending to be legally bound hereby, We, the undersigned ASSIGNORS, hereby agree to sell, assign, transfer and convey and by these presents do sell, assign, transfer and convey unto the above-named ASSIGNEE, the whole and entire right, title and interest

in and to said invention as described in the above patent application, for the territory of the United States and its possessions and territories and all foreign countries;

in and to the above patent application and any and all related United States and foreign patent applications disclosing said invention, including provisionals, non-provisionals, divisions and continuations thereof, all PCT and national phase applications, along with all rights of priority created by said patent application under any treaty relating thereto, including the right to claim priority to said patent application, e.g., under the International Convention for the Protection of Industrial Property and the European Patent Convention; and


in and to all United States and foreign patents which may be granted on any and all of said patent applications, including extensions, reissues and reexamination certificates thereof;

said invention, application(s) and patent(s) to be held and enjoyed by the above-named ASSIGNEE, for ASSIGNEE's own use and benefit, and for ASSIGNEE's legal representatives and assigns to the full end of the term or terms for which said patent(s) may be granted, as fully and entirely as the same would have been held by the undersigned ASSIGNORS had this assignment and sale not been made; and for the aforesaid consideration ASSIGNORS hereby covenant, agree and undertake to execute, whenever requested by the above-named ASSIGNEE, all patent applications, assignments, lawful oaths and any other papers which ASSIGNEE may deem necessary or desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the patent(s) hereby assigned or agreed to be assigned; all without further compensation to the undersigned ASSIGNORS.


AND ASSIGNORS acknowledge an obligation of assignment of this invention to ASSIGNEE at the time the invention was made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

5-22-18
Date


Yingzhi Bi

WITNESSED BY:


Signature: 
Name: Kristine Aylmer
Date: 5/22/18

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

May 22, 2018
Date


Bruce D. DORSEY

WITNESSED BY:

Signature: 

Name: Kristine Aylmer

Date: 5-22-18

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

5-23-18
Date

Christopher Brooks Moore
Christopher Brooks MOORE

WITNESSED BY:

Signature: K. Aylmer

Name: Kristine Aylmer

Date: 5-23-18

This assignment is accepted on behalf of **Arbutus Biopharma, Inc.** by:

5/23/18
Date

Michael J. Sofia
Name: Michael J. Sofia, Ph.D.
Title: Chief Scientific Officer

WITNESSED BY:

Signature: Kristae Aylmer
Name: Kristae Aylmer
Date: 5/23/18